Home/Pipeline/JNJ-3989

JNJ-3989

Chronic Hepatitis B

Phase 2Active

Key Facts

Indication

Chronic Hepatitis B

Phase

Phase 2

Status

Active

Company

Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Cardiopulmonary Cardiovascular Orthopaedics Surgery Vision

Other Chronic Hepatitis B Drugs

Drug	Company	Phase	Status
BRII-179 (VBI-2601)	Brii Biosciences	Phase 2	Active
BRII-835 (VIR-2218)	Brii Biosciences	Phase 2	Active
Selgantolimod (GS-9688)	Gilead Sciences	Phase 2	Active
APG-1387	Ascentage Pharma Group	Phase 2	Active
VTP-300	Barinthus Biotherapeutics	Phase 1b/2a	Active